Evidence map›Paper›PMID 26674373›Full record

Trial reportJournal of acquired immune deficiency syndromes (1999)2016

Brief Report: HIV-1 gp120 T-Cell Responses Correspond to Infection Outcomes in the Global iPrEx Chemoprophylaxis Trial.

Peter J Kuebler, Brian I Shaw, Kaitlyn S Leadabrand, Megha L Mehrotra, Robert M Grant, Esper G Kallás, Douglas F Nixon

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of acquired immune deficiency syndromes (1999), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Peter J Kuebler*Division of Experimental Medicine, University of California, San Francisco, CA;†Gladstone Institutes, San Francisco, CA;‡Department of Medicine, University of California, San Francisco, CA;§Division of Clinical Immunology and Allergy, University of São Paulo, São Paulo, Brazil; and‖Department of Microbiology, Immunology & Tropical Medicine, George Washington University, Washington, DC.
Brian I Shaw
Kaitlyn S Leadabrand
Megha L Mehrotra
Robert M Grant
Esper G Kallás
Douglas F Nixon

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Chemoprophylaxis for HIV Prevention in Men SupplementU01AI064002 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI GRANT, ROBERT M. · 2005 to 2011
$41.3M
SWG 2: Cure Research Scientific Working GroupP30AI117970 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI MICHAEL Ilya BUKRINSKY · 2015 to 2026
$29.6M
The District of Columbia Developmental Center for AIDS Research (DC D-CFAR)P30AI087714 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI GREENBERG, ALAN EDWARD · 2010 to 2014
$8.4M
Chemoprophylaxis and HIV-Host InteractionsR01AI062333 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI GRANT, ROBERT M. · 2004 to 2011
$6.2M
Protective immunity in HIV Highly exposed but uninfected subjectsR21AI087131 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NIXON, DOUGLAS F · 2010 to 2011
$647k
NCRR NIH HHS UL1 RR024131NIAID NIH HHS P30 AI087714NIAID NIH HHS P30 AI117970NIAID NIH HHS R01 AI062333NIAID NIH HHS R21 AI087131NIAID NIH HHS U01 AI064002
6 · The paper itself

Abstract

Association of HIV-1-specific T-cell responses to infection risk in seronegative individuals is controversial. We quantified and phenotypically characterized gp120-specific T-cell responses in HIV-1 exposed, but uninfected subjects enrolled in the global Pre-exposure Prophylaxis Initiative (iPrEx) chemoprophylaxis trial. IFNγ ELISpot responses were detected in 24% of subjects irrespective of infection outcome. HIV-1 gp120 envelope-specific T-cell responses were more uniformly IFN-γ+TNF-α+Mip-1β+ in persistently seronegative subjects relative to subjects who later seroconverted (median frequency of 76.5% and 66.5%, respectively). IFNγ responses targeted the V2 loop for subjects who remained seronegative. HIV-1 gp120 envelope V2 loop-specific CD8 T-cell responses may help to protect against HIV-1 acquisition.

Indexed as

ChemopreventionAIDS VaccinesCase-Control StudiesCD8-Positive T-LymphocytesCross-Sectional StudiesHIV-1HIV Envelope Protein gp120HIV InfectionsHumansLymphocyte ActivationTreatment OutcomeAIDS VaccinesHIV Envelope Protein gp120

Identifiers

PMID26674373
PMCPMC5395050

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.